JP7297685B2 - 唾液中でメラトニンを可溶性にする酸性化剤を有する経口溶解メラトニン製剤 - Google Patents
唾液中でメラトニンを可溶性にする酸性化剤を有する経口溶解メラトニン製剤 Download PDFInfo
- Publication number
- JP7297685B2 JP7297685B2 JP2019570491A JP2019570491A JP7297685B2 JP 7297685 B2 JP7297685 B2 JP 7297685B2 JP 2019570491 A JP2019570491 A JP 2019570491A JP 2019570491 A JP2019570491 A JP 2019570491A JP 7297685 B2 JP7297685 B2 JP 7297685B2
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- saliva
- composition
- acid
- melatonin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762522473P | 2017-06-20 | 2017-06-20 | |
| US62/522,473 | 2017-06-20 | ||
| PCT/US2018/037698 WO2018236678A1 (en) | 2017-06-20 | 2018-06-15 | Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020524162A JP2020524162A (ja) | 2020-08-13 |
| JP2020524162A5 JP2020524162A5 (cg-RX-API-DMAC7.html) | 2022-08-03 |
| JP7297685B2 true JP7297685B2 (ja) | 2023-06-26 |
Family
ID=64656010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570491A Active JP7297685B2 (ja) | 2017-06-20 | 2018-06-15 | 唾液中でメラトニンを可溶性にする酸性化剤を有する経口溶解メラトニン製剤 |
Country Status (13)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201912172YA (en) * | 2017-06-20 | 2020-01-30 | Physicians Seal Llc | Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva |
| US10828254B2 (en) | 2018-09-28 | 2020-11-10 | Intelgenx Corp. | Oral film formulation for modulating absorption profile |
| CN112426408B (zh) * | 2020-12-08 | 2023-12-19 | 广州帝奇医药技术有限公司 | 一种褪黑素组合物及其制备工艺 |
| US20240189331A1 (en) * | 2021-02-12 | 2024-06-13 | Intelgenx Corp. | Novel tryptamine oral film formulation |
| EP4351525A1 (en) * | 2021-06-09 | 2024-04-17 | AGB-Pharma AB | Melatonin formulation in solid dosage form |
| US12440472B2 (en) | 2021-06-16 | 2025-10-14 | Intelgenx Corp. | Stable tryptamine oral films |
| US12648905B2 (en) | 2022-01-19 | 2026-06-09 | Intelgenx Corp. | Oral films with flavor entrapment |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120195968A1 (en) | 2011-01-28 | 2012-08-02 | Shah Syed M | Controlled-release melatonin compositions and related methods |
| US20130052234A1 (en) | 2011-08-25 | 2013-02-28 | Purebrands LLC | Edible strips |
| US20140303227A1 (en) | 2013-03-14 | 2014-10-09 | Pharmaceutical Productions Inc. | Transmucosal hormone delivery system |
| JP2014237700A (ja) | 2007-04-11 | 2014-12-18 | ファーマシューティカル プロダクションズ, インコーポレイテッド | メラトニンタブレットならびに調剤及び使用方法 |
| WO2016141069A1 (en) | 2015-03-02 | 2016-09-09 | Medlab Clinical U.S., Inc. | Transmucosal and transdermal delivery systems |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030091629A1 (en) * | 1998-03-27 | 2003-05-15 | Cima Labs Inc. | Sublingual buccal effervescent |
| US6730330B2 (en) | 2001-02-14 | 2004-05-04 | Gw Pharma Limited | Pharmaceutical formulations |
| US6941948B2 (en) | 2002-03-07 | 2005-09-13 | Vectura Drug Delivery | Medicament storage and delivery devices |
| EP1696959A2 (en) | 2003-12-24 | 2006-09-06 | Sepracor, Inc. | Melatonin combination therapy for improving sleep quality |
| KR20070030178A (ko) | 2004-02-17 | 2007-03-15 | 트랜스오랄 파마슈티칼스, 인코포레이티드 | 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법 |
| US20090047347A1 (en) | 2005-07-29 | 2009-02-19 | Aegis Therapeutics, Inc. | Compositions for Drug Administration |
| WO2006037763A1 (en) * | 2004-10-05 | 2006-04-13 | Altana Pharma Ag | Oral pharmaceutical preparation for proton pump antagonists |
| CA2601969A1 (en) * | 2005-02-10 | 2006-08-17 | Orexo Ab | Pharmaceutical compositions useful in the transmucosal administration of drugs |
| WO2007095716A1 (en) | 2006-02-23 | 2007-08-30 | Iomedix Sleep International Srl | Compositions and methods for the induction and maintenance of quality sleep |
| IL175338A0 (en) * | 2006-05-01 | 2006-09-05 | Biota Ltd | Orally administrable films and preparation thereof |
| US20080171085A1 (en) | 2007-01-11 | 2008-07-17 | Natrol, Inc. | Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration |
| US20080260823A1 (en) | 2007-04-20 | 2008-10-23 | Sciele Pharma, Inc. | Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea |
| JP2010526053A (ja) * | 2007-05-01 | 2010-07-29 | シグモイド・ファーマ・リミテッド | ニモジピン医薬組成物 |
| KR100905027B1 (ko) | 2007-10-03 | 2009-06-30 | (주)씨엘팜 | 식용 필름 |
| US20110092602A1 (en) * | 2008-04-25 | 2011-04-21 | Nitin Shivcharan Laddha | Rapidly disintegrating oral compositions of tramadol |
| US20120213855A1 (en) | 2011-02-17 | 2012-08-23 | Cima Labs Inc. | Dosage forms for weakly ionizable compounds |
| US20120315337A1 (en) * | 2011-06-07 | 2012-12-13 | Shah Syed | Multiparticulate 5-htp compositions and related methods |
| ES2457718B1 (es) * | 2012-09-24 | 2015-04-16 | Universidad De Granada | Composición farmacéutica bucodispersable de melatonina |
| SG11201912172YA (en) * | 2017-06-20 | 2020-01-30 | Physicians Seal Llc | Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva |
-
2018
- 2018-06-15 SG SG11201912172YA patent/SG11201912172YA/en unknown
- 2018-06-15 US US16/009,372 patent/US10500280B2/en active Active
- 2018-06-15 RU RU2020101742A patent/RU2020101742A/ru not_active Application Discontinuation
- 2018-06-15 EP EP18820326.9A patent/EP3641759B1/en active Active
- 2018-06-15 CN CN201880041048.3A patent/CN110913853A/zh active Pending
- 2018-06-15 ES ES18820326T patent/ES2979335T3/es active Active
- 2018-06-15 JP JP2019570491A patent/JP7297685B2/ja active Active
- 2018-06-15 KR KR1020207001344A patent/KR20200018652A/ko not_active Withdrawn
- 2018-06-15 MX MX2019015733A patent/MX2019015733A/es unknown
- 2018-06-15 BR BR122021012549A patent/BR122021012549B8/pt active IP Right Grant
- 2018-06-15 WO PCT/US2018/037698 patent/WO2018236678A1/en not_active Ceased
- 2018-06-15 CA CA3067822A patent/CA3067822C/en active Active
- 2018-06-15 AU AU2018289284A patent/AU2018289284A1/en not_active Abandoned
- 2018-06-15 BR BR112019027286-0A patent/BR112019027286B1/pt active IP Right Grant
-
2019
- 2019-11-06 US US16/676,022 patent/US10960075B2/en active Active
-
2020
- 2020-05-13 US US15/931,029 patent/US11224657B2/en active Active
- 2020-05-13 US US15/931,135 patent/US11224658B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014237700A (ja) | 2007-04-11 | 2014-12-18 | ファーマシューティカル プロダクションズ, インコーポレイテッド | メラトニンタブレットならびに調剤及び使用方法 |
| US20120195968A1 (en) | 2011-01-28 | 2012-08-02 | Shah Syed M | Controlled-release melatonin compositions and related methods |
| US20130052234A1 (en) | 2011-08-25 | 2013-02-28 | Purebrands LLC | Edible strips |
| US20140303227A1 (en) | 2013-03-14 | 2014-10-09 | Pharmaceutical Productions Inc. | Transmucosal hormone delivery system |
| WO2016141069A1 (en) | 2015-03-02 | 2016-09-09 | Medlab Clinical U.S., Inc. | Transmucosal and transdermal delivery systems |
Non-Patent Citations (1)
| Title |
|---|
| :H. Munoz et al., International Journal of Pharmaceutics (2014) 467 84-89, |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018236678A1 (en) | 2018-12-27 |
| US20200268886A1 (en) | 2020-08-27 |
| KR20200018652A (ko) | 2020-02-19 |
| US11224658B2 (en) | 2022-01-18 |
| RU2020101742A (ru) | 2021-07-20 |
| AU2018289284A1 (en) | 2020-01-16 |
| US20180360967A1 (en) | 2018-12-20 |
| SG11201912172YA (en) | 2020-01-30 |
| US10960075B2 (en) | 2021-03-30 |
| US11224657B2 (en) | 2022-01-18 |
| CN110913853A (zh) | 2020-03-24 |
| US20200069803A1 (en) | 2020-03-05 |
| US20200268887A1 (en) | 2020-08-27 |
| BR122021012549B1 (pt) | 2022-02-22 |
| ES2979335T3 (es) | 2024-09-25 |
| BR122021012549B8 (pt) | 2022-10-25 |
| CA3067822A1 (en) | 2018-12-27 |
| BR112019027286A2 (pt) | 2020-07-21 |
| EP3641759B1 (en) | 2024-04-03 |
| BR112019027286B1 (pt) | 2022-02-22 |
| US10500280B2 (en) | 2019-12-10 |
| EP3641759A4 (en) | 2021-03-24 |
| JP2020524162A (ja) | 2020-08-13 |
| CA3067822C (en) | 2022-08-30 |
| MX2019015733A (es) | 2020-02-20 |
| EP3641759A1 (en) | 2020-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11224657B2 (en) | Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva | |
| Dixit et al. | Oral strip technology: Overview and future potential | |
| DK2701681T3 (en) | PHARMACEUTICAL COMPOSITIONS COMPRISING A LOCAL ANESTHETICS as bupivacaine for local administration to the mouth or throat | |
| EP4076380B1 (en) | Transmucosal therapeutic system containing agomelatine | |
| Chauhan et al. | A comprehensive review on mucoadhesive drug delivery | |
| EP4076381B1 (en) | Transmucosal therapeutic system containing agomelatine | |
| JP5284070B2 (ja) | 口腔内粘膜貼付製剤 | |
| CN110650732A (zh) | 锭剂剂型 | |
| US20180318228A1 (en) | Method for a slow release of drugs from orally dissolving capsules | |
| WO2022157563A1 (en) | A pharmaceutical composition comprising lidocaine and melatonin | |
| Nagpal et al. | Patent innovations in fast dissolving/disintegrating dosage forms | |
| HK40019696A (en) | Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva | |
| Singh et al. | A review on mouth dissolving film-a novel approach | |
| Repka et al. | Matrix-and reservoir-based transmucosal delivery systems: tailoring delivery solutions | |
| HK40110942A (en) | Transmucosal therapeutic system containing agomelatine | |
| JP2011201817A (ja) | 口腔貼付用錠剤 | |
| CN107296798A (zh) | 抗发红组合物 | |
| TW201801717A (zh) | 包含局部麻醉劑之快速崩解口腔薄膜 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210609 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20210805 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220323 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220426 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20220722 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221122 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230217 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230530 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230614 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7297685 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |